A Study of Extended Total Mesopancreas Excision(eTME) for Pancreatic Head Adenocarcinoma.

• Conditions: Pancreas Adenocarcinoma

• Registration Number: NCT04147403
• Lead Sponsor: Shanghai Jiao Tong University School of Medicine

Brief Summary

The study of extended total mesopancreas excision(eTME) for pancreatic head adenocarcinoma is a retrospective multicenter cohort, collecting medical records and follow-up data of patients who underwent radical resection with pancreatic head adenocarcinoma.

Detailed Description

The objectives of the study are as follows:

1. To evaluate the perioperative safety of extended total mesopancreas excision(eTME) for patients who diagnosed with resectable pancreatic head adenocarcinoma.

2. To demonstrate the prognosis of extended total mesopancreas excision(eTME) for patients who diagnosed with resectable pancreatic head adenocarcinoma.

Study Timeline

• Study Start: 2008-01-01
• Primary Completion: 2018-10-31
• Status Verified: 2019-10
• Study First Submitted: 2019-10-30
• Study First Submitted QC: 2019-10-30
• Last Update Submitted: 2019-10-30
• Study First Posted: 2019-11-01
• Last Update Posted: 2019-11-01
• Study Completion: 2020-10-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

1. Patients with pancreatic head adenocarcinoma who underwent curative-intent resection.
2. Patients with accessible medical records

Exclusion Criteria

1. Patients with unknown chemotherapy sequence or status
2. Patients with history of previous malignant tumors
3. Patients with distant metastases

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Overall survival	5 years	The overall survival data were defined by (date of death)-(date of first diagnosis).The survival status of patients were retrieved from follow-up.

Secondary Outcome Measures

Name	Time	Method
Disease free survival	5 years	The overall survival data were defined by (date of recurrence/progression)-(date of surgery).During follow-up period, abdominal enhanced CT, chest X-ray, tumor markers and routine blood tests were carried out to evaluate recurrence/progression.

Trial Locations

Locations (4)

Ruijin Hospital,Affiliated to Shanghai Jiaotong University School of Medicine; 🇨🇳 Shanghai, Shanghai, China

Zhongshan Hospital, Fudan University; 🇨🇳 Shanghai, Shanghai, China

Changhai Hospital Affiliated to Naval Medical University; 🇨🇳 Shanghai, Shanghai, China

Xinhua Hospital, Affiliated to Shanghai Jiao Tong University, School of Medicine; 🇨🇳 Shanghai, Shanghai, China